Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

Author： Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.30, Iss.4, 2014-04, pp. : 645-653

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

By Deitelzweig Steve   Amin Alpesh   Jing Yonghua   Makenbaeva Dinara   Wiederkehr Daniel   Lin Jay   Graham John  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1163-1168

Informa Healthcare

Access to resources Recommend Favorite

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation

By Amin Alpesh   Stokes Michael   Wu Ning   Gatt Elyse   Makenbaeva Dinara   Wiederkehr Daniel   Boulanger Luke  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1193-1202

Informa Healthcare

Access to resources Recommend Favorite

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 8, 2015-08 ,pp. : 1405-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

By Currie Craig J.   McEwan Phil   Emmas Cathy   Morgan Christopher Ll.   Peters John R.  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1905-1913

Informa Healthcare

Access to resources Recommend Favorite